Company intelligence / Profile preview

Freedom Meditech

San Diego, California, United Statesfacebook.com ↗

Ownership: Private
Development stage: Commercial

Overview

Freedom Meditech developed and commercialized ophthalmic medical devices, notably the FDA-cleared ClearPath DS120 for non-invasive measurement of lens autofluorescence to detect diabetes biomarkers. The company also developed I-SugarX, a non-invasive glucose monitor using ocular measurements, which was in development as of its acquisition. Clinical studies demonstrated effectiveness in non-invasively measuring glucose via the eye. The company was acquired on January 6, 2017.

Therapeutic areas: OtherEndocrinology
Modalities: DeviceNon-pharmacological therapy (diagnostic)
Industry: Physiological Monitoring

Drug pipeline

2 assets

ClearPath DS-120

Commercial

Indications: Diabetes screening

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Freedom Meditech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Freedom Meditech.

Explore the full profile